Preliminary safety and efficacy of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (IBR) in patients (pts) with hairy cell leukemia (HCL)

7063 Background: Effective treatments (tx) for classical (c) HCL pts refractory to or ineligible for nucleoside analogs (NA) are limited, and there is no accepted standard for either tx-naive or re...